PD-L1 is expressed in 20–50% of human tumors and can provide immune evasion in many cancers by its overexpression (PD-L1 or PD-L2) and an augmented tumor immune response by its (PD-1) abrogated ligand interaction [22]. Here, CD274 is linked to cancer.